TREATMENT WITH A CXCR4 ANTAGONIST CURES DIABETES IN NOD MICE

被引：0
|
作者：
Schwarznau, Alice [1 ]
Barwig, Anja [1 ]
Bourquain, Ulrike [2 ]
Auer, Veronika [2 ]
Schantz, Nikolaus [2 ]
Stangl, Manfred J. [1 ]
机构：
[1] Tech Univ Munich, Klinikum Rechts Isar, Dept Surg, Div Transplantat, D-8000 Munich, Germany
[2] Tech Univ Munich, IMETUM, D-8046 Garching, Germany
来源：
TRANSPLANT INTERNATIONAL | 2009年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：5 / 5
页数：1
相关论文
共 50 条
  • [21] Erratum to: Comparison of 18F-labeled CXCR4 antagonist peptides for PET imaging of CXCR4 expression
    Xiao-Xiang Zhang
    Zhongchan Sun
    Jinxia Guo
    Zhe Wang
    Chenxi Wu
    Gang Niu
    Ying Ma
    Dale O. Kiesewetter
    Xiaoyuan Chen
    Molecular Imaging and Biology, 2013, 15 : 788 - 788
  • [22] EPI-X4, a novel endogenous antagonist of CXCR4
    Buske, Christian
    Kirchhoff, Frank
    Muench, Jan
    ONCOTARGET, 2015, 6 (34) : 35137 - 35138
  • [23] Anti-angiogenic activity of the CXCR4 antagonist balixafortide
    Zimmermann, Johann
    Obrecht, Daniel
    Remus, Tobias
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [24] A novel CXCR4 antagonist for hematopoietic stem cell mobilization
    Fricker, Simon P.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2008, 17 (11) : 1749 - 1760
  • [25] Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells
    Uy, Geoffrey L.
    Rettig, Michael P.
    Cashen, Amanda F.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2008, 8 (11) : 1797 - 1804
  • [26] Engraftment of acute myeloid leukemia in NOD/SCID mice is independent of CXCR4 and predicts poor patient survival
    Monaco, G
    Konopleva, M
    Munsell, M
    Leysath, C
    Wang, RY
    Jackson, CE
    Korbling, M
    Estey, E
    Belmont, J
    Andreeff, M
    STEM CELLS, 2004, 22 (02) : 188 - 201
  • [27] A novel small molecule CXCR4 antagonist potently mobilizes hematopoietic stem cells in mice and monkeys
    Xiao Fang
    Xiong Fang
    Yujia Mao
    Aaron Ciechanover
    Yan Xu
    Jing An
    Ziwei Huang
    Stem Cell Research & Therapy, 12
  • [28] A single treatment with microcapsules containing a CXCR4 antagonist suppresses pulmonary metastasis of murine melanoma
    Takenaga, M
    Tamamura, H
    Hiramatsu, K
    Nakamura, N
    Yamaguchi, Y
    Kitagawa, A
    Kawai, S
    Nakashima, H
    Fujii, N
    Igarashi, R
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 320 (01) : 226 - 232
  • [29] Mavorixafor, CXCR4 antagonist, a novel treatment for WHIM syndrome, first FDA approval 2024
    Waheed, Aiman
    Gul, Muhammad Hamza
    Ilmaguook, Badr
    Wardak, Abdul Baseer
    Sadeed, Fnu
    Hussaini, Helai
    Ahmad, Sarah
    ANNALS OF MEDICINE AND SURGERY, 2025, 87 (04): : 1777 - 1779
  • [30] Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome
    Dale, David C.
    Firkin, Frank C.
    Bolyard, Audrey Anna
    Kelley, Merideth
    Makaryan, Vahagn
    Gorelick, Kenneth J.
    Ebrahim, Tarek
    Garg, Varun
    Tang, Weihua
    Jiang, Honghua
    Skerlj, Renato
    Cohen, Sarah L. Beaussant
    BLOOD, 2020, 136 (26) : 2994 - 3003
12345